Galectin Therapeutics Inc (GALT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.61+5.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GALT
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-18.8) + peer(0.2*6.7) + term(0.0) → -5.23% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 14, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the his…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 15, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histor…
Results of Operations and Financial Condition. On March 31, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…
Results of Operations and Financial Condition. On November 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the nine months ended September 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except f…
Results of Operations and Financial Condition. On August 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the his…
Results of Operations and Financial Condition. On May 15, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2025 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…
Results of Operations and Financial Condition. On March 31, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historic…
Results of Operations and Financial Condition. On November 14, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended September 30, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 14, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except f…
Results of Operations and Financial Condition. On August 13, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended June 30, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 13, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the hi…
Results of Operations and Financial Condition. On May 15, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…
Results of Operations and Financial Condition. On March 29, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 29, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historic…
Results of Operations and Financial Condition. On November 13 , 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended September 30, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 13, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1…
Results of Operations and Financial Condition. On November 13 , 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended September 30, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 13, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1…
Results of Operations and Financial Condition. On August 14, 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and six months ended June 30, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except fo…
Results of Operations and Financial Condition. On May 15, 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2022 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historical i…
Results of Operations and Financial Condition. On March 30, 3023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2022 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 30, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historic…